Patients with heart failure (HF) fall into two categories—those who are stable and ambulatory with a relatively low event rate, and patients requiring hospitalization who are characterized by high post-discharge mortality and rates of rehospitalization. HF trials in 2010 contributed to the advancement of outpatient management, whereas the development of novel therapies with a survival benefit remains an unmet need in acute HF syndromes.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Garlic extracts prevent oxidative stress, hypertrophy and apoptosis in cardiomyocytes: a role for nitric oxide and hydrogen sulfide
BMC Complementary and Alternative Medicine Open Access 29 August 2012
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Gheorghiade, M. & Pang, P. S. Acute heart failure syndromes. J. Am. Coll. Cardiol. 53, 557–573 (2009).
Swedberg, K. et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376, 875–885 (2010).
Zannad, F. et al. Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. doi:10.1056/NEJMoa1009492.
Tang, A. S. et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N. Engl. J. Med. 363, 2385–2395 (2010).
Massie, B. M. et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N. Engl. J. Med. 363, 1419–1428 (2010).
Pitt, B. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 341, 709–717 (1999).
Pitt, B. et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348, 1309–1321 (2003).
Juurlink, D. N. et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N. Engl. J. Med. 351, 543–551 (2004).
Cotter, G. et al. The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. J. Card. Fail. 14, 631–640 (2008).
Hernandez, A. F. Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). Presented at the 2010 AHA Scientific Sessions, Chicago, IL, USA.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M. Gheorghiade has received grants/research support from Bayer, Debiopharm, Medtronic, Novartis, Otsuka, PeriCor, Sigma-Tau, and Solvay Pharmaceuticals; and has been a consultant for Abbott, Astellas, AstraZeneca, Bayer, Corthera, Cytokinetics, Debiopharm, Errekappa Euroterapici, GlaxoSmithKline, Johnson & Johnson, Medtronic, Merck, Novartis, Otsuka, PDL BioPharma, PeriCor, Scios, Sigma-Tau, and Solvay Pharmaceuticals. A. Ambrosy declares no competing interests.
Rights and permissions
About this article
Cite this article
Gheorghiade, M., Ambrosy, A. One step forward, two steps back. Nat Rev Cardiol 8, 72–73 (2011). https://doi.org/10.1038/nrcardio.2010.205
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2010.205
This article is cited by
-
Global Perspectives in Hospitalized Heart Failure: Regional and Ethnic Variation in Patient Characteristics, Management, and Outcomes
Current Heart Failure Reports (2014)
-
Garlic extracts prevent oxidative stress, hypertrophy and apoptosis in cardiomyocytes: a role for nitric oxide and hydrogen sulfide
BMC Complementary and Alternative Medicine (2012)
